Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively.

Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.